Skip to main content
LTR PHARMA LIMITED logo

LTR PHARMA LIMITED — Investor Relations & Filings

Ticker · LTP ISIN · AU0000305294 ASX Manufacturing
Open in API
Filings indexed 130 across all filing types
Latest filing 2026-04-30 Legal Proceedings Report
Country AU Australia
Listing ASX LTP

About LTR PHARMA LIMITED

https://ltrpharma.com

LTR Pharma Limited focuses on the development and commercialization of innovative therapies for men’s health. The company’s lead product candidate, SPONTAN, is a proprietary nasal spray formulation of vardenafil designed for the treatment of erectile dysfunction. Utilizing a unique delivery platform, SPONTAN is engineered to provide a significantly faster onset of action compared to traditional oral medications. By leveraging advanced drug delivery technology to bypass first-pass metabolism, the formulation aims to improve patient outcomes and reduce the time to efficacy. LTR Pharma is dedicated to advancing its clinical programs through regulatory pathways to provide rapid-acting solutions for men’s health conditions.

Recent filings

Filing Released Lang Actions
SPONTAN Phase II data show rapid onset, support FDA pathway 6 pages 280.1KB
Legal Proceedings Report Classification · 95% confidence The document is an announcement from LTR Pharma reporting interim Phase II clinical trial data for their drug SPONTAN®. It includes detailed pharmacokinetic and safety data, study design, and regulatory pathway information. The document is not a full annual or quarterly financial report, nor is it a regulatory filing or certification. It is not a call transcript, AGM material, or a voting result announcement. The content focuses on clinical trial interim results and regulatory progress, which is typical of a Legal Proceedings Report (LTR) when related to regulatory or clinical trial updates. The document is lengthy (over 12,000 characters) and contains substantive data and analysis, not just a brief announcement or summary. Therefore, the best fitting category is Legal Proceedings Report (LTR), as it relates to regulatory and clinical trial updates relevant to the company.
2026-04-30 English
Investor Presentation 24 pages 2.6MB
Investor Presentation Classification · 95% confidence The document is an investor update presentation from LTR Pharma dated May 2026. It contains detailed information about the company's pharmaceutical product pipeline, clinical trial data (Phase I and Phase II), market analysis, regulatory pathways, commercial validation, and strategic partnerships. The content is structured as a presentation with slides, charts, and data summaries aimed at investors. There is no indication that this is a regulatory filing, audit report, earnings release, or legal proceeding update. It is not a full annual or interim financial report but rather a detailed investor presentation focusing on product development, market opportunity, and company strategy. Therefore, the document best fits the category of Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2026-04-30 English
Trading Halt 3 pages 220.7KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from LTR Pharma Limited regarding a trading halt requested by the company pending the release of an announcement related to interim clinical trial results. It is a short notice explaining the trading halt and does not contain any financial data, detailed report, or analysis. It is not a full report, earnings release, or any detailed filing but rather a regulatory announcement to the market about trading status. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-04-28 English
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 392.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report & Appendix 4C' for the period ending 31 March 2026. It includes detailed operational updates, clinical development progress, commercialisation strategy, financial position, and a comprehensive Appendix 4C cash flow report as required by ASX Listing Rule 4.7B. The content is focused on quarterly activities and financial cash flow data rather than a full annual report or audit. The presence of the Appendix 4C, which is a quarterly cash flow report, and the detailed narrative on quarterly progress and financials clearly indicate this is an Interim / Quarterly Report. The document length (15,000 characters) and substantive financial data confirm it is not merely an announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q3 2026
2026-04-27 English
Investor Presentation 22 pages 2.4MB
Investor Presentation Classification · 95% confidence The document is a detailed investor update presentation from LTR Pharma Ltd dated March 2026. It contains extensive information about the company's pharmaceutical product pipeline, clinical data, regulatory pathways, market strategy, partnerships, and financial position. The content is structured as a presentation with slides, including forward-looking statements, disclaimers, and detailed scientific and commercial data. There are no financial statements, audit opinions, or regulatory certifications. It is not an earnings release or a formal annual or interim report. The document is clearly intended for investors and provides a comprehensive overview of the company's strategy, product development, and market positioning. This matches the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2026-03-10 English
SPONTAN Phase II Clinical Study Completes Recruitment 2 pages 152.1KB
Legal Proceedings Report Classification · 90% confidence The document is a company announcement dated 5 March 2026 about the completion of recruitment for a Phase II clinical study of a pharmaceutical product. It provides highlights of the study progress, details about the cohorts, and mentions expected data release in Q2 CY2026. The content is focused on clinical trial progress and regulatory pathway steps, not on financial results, management changes, or shareholder votes. The document is relatively short (4284 characters) and reads as a news release or update rather than a detailed report or transcript. It does not contain financial statements, audit information, or detailed governance disclosures. It is an announcement about clinical study progress, which fits best under Legal Proceedings Report (LTR) as it relates to regulatory and clinical trial updates, or Regulatory Filings (RNS) as a fallback. However, since it is specifically about clinical study progress and regulatory pathway steps, the best fit is Legal Proceedings Report (LTR).
2026-03-04 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.